Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Status:
Enrolling by invitation
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to observe the long-term safety of filgotinib in
adults who have completed or met protocol specified efficacy discontinuation criteria in a
prior Gilead-sponsored filgotinib treatment study in Crohn's disease (CD).